Philip Davies
Research Subjects
Philip Davies has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Chris J.L.M. Meijer
Department of Pathology, VU University Medical Centre, Amsterdam, The Netherlands
1 shared publicationGuglielmo Ronco
Centro per l'Epidemiologia e la Prevenzione dei Tumori (CPO), Torino, Italy
1 shared publicationHenry C. Kitchener
Academic Unit of Obstetrics and Gynaecology and Reproductive Health Care, St Mary's Hospital, Manchester, United Kingdom
1 shared publicationJoakim Dillner
Department of Medical Microbiology, Lund University, Malmö University hospital, Malmö, Sweden
1 shared publicationMarc Arbyn
Scientific Institute of Public Health, Brussels, Belgium
1 shared publicationMatti Hakama
University of Tampere, School of Public Health, Tampere, Finland
1 shared publication
Latest Publications
- Open Access
- 13 December 2005
- Published by Wiley in International Journal of Cancer
- Vol. 118 (4) , 791-796
A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening
Cervical cancer remains a significant public health concern, both at a global and a European level. A number of new technologies such as diagnostic tests for human papillomavirus (HPV) have a potential to assist with the reduction of this disease. However, both the efficacy and the cost‐effectiveness of these new technologies must be established in properly designed trials before they can be implemented within national public health programs. Our study reviews the randomized controlled trials that are currently being conducted in Europe to establish the performance of HPV testing as a primary cervical cancer screening test.
- 13 December 2005
- Published by Wiley in International Journal of Cancer
- Vol. 118 (4) , 791-796
Open AccessA report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening
Cervical cancer remains a significant public health concern, both at a global and a European level. A number of new technologies such as diagnostic tests for human papillomavirus (HPV) have a potential to assist with the reduction of this disease. However, both the efficacy and the cost‐effectiveness of these new technologies must be established in properly designed trials before they can be implemented within national public health programs. Our study reviews the randomized controlled trials that are currently being conducted in Europe to establish the performance of HPV testing as a primary cervical cancer screening test.